Our Take
NICE reversed its initial rejection to fund a four-drug combination that improves remission rates by 21 percentage points in the two-thirds of myeloma patients ineligible for transplant, but the approval rests entirely on one company-sponsored trial with no independent reproduction.
Why it matters
Two-thirds of newly diagnosed myeloma patients cannot receive autologous stem cell transplants and face limited first-line options; this approval expands the toolkit for UK clinicians. The reversal also signals that patient advocacy and sponsor resubmission can move NICE on marginal clinical gains.
Do this week
UK haematologists: audit your transplant-ineligible myeloma intake protocols this quarter to identify eligible patients for D-VRd initiation under the new funding pathway.
NICE reverses course on daratumumab combination
The UK's National Institute for Health and Care Excellence has issued final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for NHS funding in adults with newly diagnosed multiple myeloma who are unsuitable for autologous stem cell transplant. This is the only licensed subcutaneous CD38-directed antibody quadruplet approved for first-line use in this population in the UK.
The decision reverses NICE's earlier rejection. Myeloma UK, the patient advocacy organisation, said it had "worked very hard to get NICE to reconsider" and described the outcome as a "hard-earned victory for patients who felt let down" by the initial stance.
The recommendation is based on the phase 3 CEPHEUS trial, which compared D-VRd to the three-drug triplet regimen (daratumumab, lenalidomide, dexamethasone without bortezomib). At a median follow-up of 58.7 months, D-VRd achieved a 60.9% overall minimal residual disease-negativity rate compared with 39.4% for the triplet (company-reported). Bortezomib, a proteasome inhibitor in clinical use for decades, is the novel addition to the combination.
Multiple myeloma affects approximately 33,000 people in the UK and remains incurable. The disease becomes progressively harder to treat with each relapse, which is why clinicians emphasise effective first-line therapy. Roughly two-thirds of newly diagnosed patients are ineligible for transplant, either due to age or comorbidities.
Clinical gain is real but narrow, and evidence is sponsor-owned
A 21-percentage-point improvement in minimal residual disease-negativity is measurable and clinically relevant. Patients achieving MRD-negative status typically experience longer progression-free survival and delayed need for subsequent therapies, which translates to fewer hospital visits and improved quality of life in the years immediately after diagnosis.
However, the evidence base is constrained. CEPHEUS is a single phase 3 trial sponsored by Johnson & Johnson (which manufactures daratumumab). There is no independent reproduction of these results, no published peer-reviewed comparison against other quadruplet regimens, and no head-to-head data against alternative standard-of-care combinations for transplant-ineligible patients. The approval hinges entirely on this one company-funded dataset.
The reversal itself is noteworthy. Organised patient advocacy, combined with sponsor resubmission, was sufficient to move NICE from rejection to recommendation on a single-digit improvement in one surrogate endpoint. This may signal a lower bar for appraising combination therapies in oncology when patient need is high and the disease is incurable.
What haematologists should do now
UK clinicians should verify that their myeloma intake processes can identify transplant-ineligible newly diagnosed patients eligible for D-VRd under the new NHS funding. This includes confirming age and fitness criteria, reviewing access pathways with local pharmacy, and ensuring patients and families understand that MRD-negativity is the measured benefit, not progression-free survival directly.
The approval applies only to newly diagnosed, untreated patients. Clinicians should not apply D-VRd to relapsed disease or patients who have already received prior therapy, as CEPHEUS enrolled treatment-naïve cohorts only and there is no evidence of efficacy in pre-treated populations.